Nurix Therapeutics, Inc. Common stock Stock Prediction
AI-powered sentiment analysis and prediction trends for NRIX, updated each market day.
NRIX AI Sentiment
AI predicts Nurix Therapeutics, Inc. Common stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Sector
Exchange
Market Cap
$1,679,310,403
Cap Tier
Employees
357
Headquarters
BRISBANE, CA
Listed Since
July 24, 2020
Website
NRIX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NRIX Volatility
Nurix Therapeutics, Inc. Common stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
